1.
Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial
by Younes, Anas, Prof
The lancet oncology, 2016, Vol.17 (9), p.1283-1294
2.
Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial
by Engert, Andreas, MD
The Lancet (British edition), 2012, Vol.379 (9828), p.1791-1799
3.
PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial
by Borchmann, Peter
The lancet oncology, 2021, Vol.22 (2), p.223-234
4.
PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study...
by Borchmann, Peter
The Lancet (British edition), 2017, Vol.390 (10114), p.2790-2802
5.
Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1–2 trial
by O'Connor, Owen A
The lancet oncology, 2018, Vol.19 (2), p.257-266
6.
Evaluation of the diagnostic and prognostic value of PDL1-expression in Hodgkin- and B-cell lymphomas
by Menter, Thomas
Human pathology, 2016, Vol.54, p.17-24
7.
PET-guided omission of radiotherapy in Hodgkin lymphoma – Authors' reply
by Borchmann, Peter
The lancet oncology, 2021, Vol.22 (5), p.e182-e182
8.
Hodgkin's lymphoma in adults
by Townsend, William, MBChB
The Lancet (British edition), 2012, Vol.380 (9844), p.836-847
9.
Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1–2 trial
by Davis, Kara L
The lancet oncology, 2020, Vol.21 (4), p.541-550
10.
PET-guided omission of radiotherapy in Hodgkin lymphoma
by Shibusawa, Motoharu
The lancet oncology, 2021, Vol.22 (5), p.e181-e181
11.
Novel mutations in TNFRSF7 / CD27 : Clinical, immunologic, and genetic characterization of human CD27 deficiency
by Alkhairy, Omar K., MD
Journal of allergy and clinical immunology, 2015, Vol.136 (3), p.703-712.e10
12.
Microenvironmental interactions in classical Hodgkin lymphoma and their role in promoting tumor growth, immune escape and drug resistance
by Aldinucci, Donatella
Cancer letters, 2015, Vol.380 (1), p.243-252
13.
Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial
by Younes, Anas, Prof
The lancet oncology, 2011, Vol.12 (13), p.1222-1228
14.
Brentuximab vedotin with gemcitabine for paediatric and young adult patients with relapsed or refractory Hodgkin's lymphoma (AHOD1221): a Children's Oncology Group, multicentre sin...
by Cole, Peter D
The lancet oncology, 2018, Vol.19 (9), p.1229-1238
15.
Cancer Risks in Patients Treated With Growth Hormone in Childhood: The SAGhE European Cohort Study
by Swerdlow, AJ
The journal of clinical endocrinology and metabolism, 2017, Vol.102 (5), p.1661-1672
16.
Diffusion-weighted MRI of lymphoma: prognostic utility and implications for PET/MRI?
by Punwani, Shonit
European journal of nuclear medicine and molecular imaging, 2012, Vol.40 (3), p.373-385
17.
Cumulative burden of cardiovascular morbidity in paediatric, adolescent, and young adult survivors of Hodgkin's lymphoma: an analysis from the St Jude Lifetime Cohort Study
by Bhakta, Nickhill, Dr
The lancet oncology, 2016, Vol.17 (9), p.1325-1334
18.
Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 s...
by Kuruvilla, John
The lancet oncology, 2021, Vol.22 (4), p.512-524
19.
Trends in cancer risk among people with AIDS in the United States 1980-2002
by ENGELS, Eric A
AIDS (London), 2006, Vol.20 (12), p.1645-1654
20.
Determinants of ovarian function after response-adapted therapy in patients with advanced Hodgkin's lymphoma (RATHL): a secondary analysis of a randomised phase 3 trial
by Anderson, Richard A
The lancet oncology, 2018, Vol.19 (10), p.1328-1337
